Relmada Therapeutics (RLMD) to Release Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) will be releasing its earnings data after the market closes on Thursday, November 7th. Analysts expect Relmada Therapeutics to post earnings of ($0.65) per share for the quarter.

Relmada Therapeutics (NASDAQ:RLMD) last issued its earnings results on Wednesday, August 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.24. During the same period in the prior year, the firm earned ($0.84) earnings per share. On average, analysts expect Relmada Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Relmada Therapeutics Stock Down 2.9 %

NASDAQ RLMD traded down $0.10 during trading hours on Tuesday, hitting $3.32. 60,159 shares of the company were exchanged, compared to its average volume of 181,795. Relmada Therapeutics has a 52 week low of $1.88 and a 52 week high of $7.22. The stock has a 50-day moving average price of $3.26 and a 200 day moving average price of $3.30. The stock has a market cap of $100.16 million, a PE ratio of -1.15 and a beta of 0.41.

Analyst Ratings Changes

Separately, Jefferies Financial Group raised shares of Relmada Therapeutics from a “hold” rating to a “buy” rating and lifted their price target for the company from $3.50 to $13.00 in a research report on Tuesday, September 17th.

Insider Buying and Selling

In other news, CEO Sergio Traversa acquired 55,579 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were purchased at an average cost of $2.71 per share, for a total transaction of $150,619.09. Following the transaction, the chief executive officer now directly owns 299,603 shares in the company, valued at $811,924.13. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Maged Shenouda acquired 24,120 shares of Relmada Therapeutics stock in a transaction that occurred on Wednesday, September 11th. The shares were acquired at an average price of $2.95 per share, with a total value of $71,154.00. Following the purchase, the chief financial officer now directly owns 88,335 shares of the company’s stock, valued at $260,588.25. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sergio Traversa bought 55,579 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were purchased at an average price of $2.71 per share, for a total transaction of $150,619.09. Following the completion of the acquisition, the chief executive officer now owns 299,603 shares of the company’s stock, valued at $811,924.13. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 152,300 shares of company stock worth $429,655. 18.00% of the stock is owned by insiders.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.